Drug Use Investigation for TYKERB Tablet (All Case Investigation)
N/A
N/A
N/A
N/A
N/A
Open (Enrolling)
Both
Cancer
Both
Cancer
Trial Information
Drug Use Investigation for TYKERB Tablet (All Case Investigation)
Inclusion Criteria:
- Patients with HER2 overexpressing inoperable or recurrent breast cancer
Exclusion Criteria:
- Patients with hypersensitivity to lapatinib or any components
- Pregnant women and women suspected of being pregnant
Type of Study:
Observational
Study Design:
N/A
Outcome Measure:
The incidence of adverse events in Japanese patients treated with TYKERB based on prescribing information under the conditions of general clinical practice
Outcome Time Frame:
1 year
Safety Issue:
Yes
Principal Investigator
GSK Clinical Trials
Investigator Role:
Study Director
Investigator Affiliation:
GlaxoSmithKline
Authority:
Japan: Pharmaceuticals and Medical Devices Agency
Study ID:
113092
NCT ID:
NCT01332396
Start Date:
June 2009
Completion Date:
July 2016
Related Keywords:
- Cancer
Name | Location |
|---|
